Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

USP13 inhibits afatinib. 3 / 3

| 1 2

➶

reach

"Overall, these data indicate that targeting of USP13 strongly potentiates the anticancer effects of afatinib in vivo."

33210294

➶

reach

"Similar results were obtained in HCC827 cells, confirming that USP13 knockdown strongly enhances afatinib in treatment-naive lung cancer cell lines."

33210294

➶

eidos

"Similar results were obtained in HCC827 cells ( Figure 2D ) , confirming that USP13 knockdown strongly enhances afatinib in treatment-naive lung cancer cell lines ."

33210294

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...

Other Services

This Service

This Project

IndraLab

Statements

USP13 inhibits afatinib. 3 / 3

Our Sources:

Databases

Reading